earnings
confidence high
sentiment positive
materiality 0.80
Gilead Q4/FY2025: revenue up 5% to $7.9B Q4, full-year EPS $6.78; guides 2026 sales $29.6-30B
GILEAD SCIENCES, INC.
2025-FY EPS reported
$6.78
revenue$29,443,000,000
- Q4 GAAP diluted EPS $1.74 vs $1.42 YoY; non-GAAP diluted EPS $1.86 vs $1.90.
- Q4 product sales up 5% to $7.9B; HIV sales up 6% to $5.8B; Biktarvy $4.0B (+5%).
- Full year 2025 total revenues $29.4B (+2%); product sales ex-Veklury $28.0B (+4%).
- Full year GAAP diluted EPS $6.78 vs $0.38; non-GAAP $8.15 vs $4.62.
- FY2026 guidance: product sales $29.6-30B, non-GAAP diluted EPS $8.45-8.85.